Curevac AG
CureVac AG, a pioneering biopharmaceutical company headquartered in Tübingen, Germany, is at the forefront of mRNA technology. Founded in 2000, CureVac has made significant strides in the development of innovative therapies and vaccines, particularly in the fields of oncology and infectious diseases. The company is renowned for its proprietary mRNA platform, which enables the creation of targeted treatments that harness the body’s own immune response. Notable achievements include the advancement of its COVID-19 vaccine candidate, which showcased the potential of mRNA in rapid vaccine development. With a strong market position and collaborations with leading pharmaceutical companies, CureVac AG continues to drive advancements in the biotechnology sector, aiming to transform the landscape of medicine through its unique approach to mRNA therapeutics.
DitchCarbon Score
How does Curevac AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Curevac AG's score of 22 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Curevac AG's reported carbon emissions
Curevac AG, headquartered in Germany, currently does not report specific carbon emissions data for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of CureVac N.V., which may influence its climate reporting and commitments. Curevac AG has not established any documented reduction targets or specific climate pledges at this time. The absence of data suggests that the company may still be in the process of developing its climate strategy or reporting framework. As a part of the biopharmaceutical industry, Curevac AG is positioned within a sector that is increasingly focusing on sustainability and carbon reduction. While no specific emissions data or targets are available, the company’s affiliation with CureVac N.V. may provide opportunities for alignment with broader corporate sustainability initiatives. In summary, while Curevac AG has not disclosed specific emissions data or reduction commitments, its corporate structure may play a role in shaping its future climate strategies.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Curevac AG is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
